ReviewKidney & blood pressure research2026
Monkeypox Infection in Kidney Transplant Recipients.
Review in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mpox in Solid Organ Transplant Recipients: Lessons From a Single-Center Case Series in South Florida.Transplant infectious disease : an official journal of the Transplantation SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe monkeypox virus is currently circulating in Africa and has been declared a public health emergency of international concern. Due to lifelong immunosuppressive therapy, kidney transplant recipients are susceptible to infections and at high risk for developing serious complications. SUMMARY: We summarized the clinical data of 11 patients from the database. A total of 10 cases occurred in males, with age ranging from 25 to 62 years old. Common clinical features include rashes, anorectal pain, fever, pharyngitis, diarrhea, dyspnea and abdominal pain. Median duration of symptoms at presentation was 54 days (range, 21-120 days). Once diagnosed, immunosuppressive agents were adjusted among seven patients (7/11). A total of 10 cases received antiviral medication including tecovirimat, cidofovir and brincidofovir. The median time to initiate treatment was 16.5 days (range, 4-35 days). The majority (10/11) had a good prognosis, with one monkeypox-related death in the cohort. KEY MESSAGES: Monkeypox infection is spreading fast over the world and presents a major concern to kidney transplant recipients. In this immunocompromised group, we should focus more on effective preventative and treatment techniques. Further research is needed to standardize management algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.